Originally doing business as NeoTherapeutics and then as Advanced Immonotherapeutics, in 2002 the firm changed its name Spectrum Pharmaceuticals. With limited SBIR involvement and that soon after firm was establsihed, Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) had six drug products, including FUSILEV for patients with metastatic colorectal cancer, rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor to treat patients with relapsed or refractory PTCL; ZEVALIN injection for patients with follicular non-HodgkinÂs lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer; and POZIOTINIB for treating breast and lung cancer. The company sells its drugs through a direct sales force in the United States; and through distributors in Europe. Spectrum Pharmaceuticals, Inc. has an aggressive program of licensing in and out nationally and internationally having agreements with a rnage of fir to include Cell Therapeutics, Inc.; Merck & Cie AG, Sloan-Kettering Institute, and Cydex Pharmaceuticals, Inc.; Allergan, Inc.; Nippon Kayaku Co., LTD.; Onxeo DK; Hanmi Pharmaceutical Company.